Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given an average rating of “Hold” by the twenty-six ratings firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $137.76.

A number of research analysts recently commented on ZBH shares. BMO Capital Markets reissued a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet Holdings in a report on Tuesday, July 11th. Canaccord Genuity reissued a “buy” rating on shares of Zimmer Biomet Holdings in a report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 price target on Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Friday, April 28th. Jefferies Group LLC reissued a “buy” rating and issued a $148.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, June 30th. Finally, Guggenheim raised Zimmer Biomet Holdings from a “neutral” rating to a “buy” rating and set a $157.00 price target for the company in a report on Wednesday, July 12th.

Shares of Zimmer Biomet Holdings (NYSE:ZBH) opened at 117.19 on Tuesday. Zimmer Biomet Holdings has a 12 month low of $95.63 and a 12 month high of $133.49. The stock’s 50 day moving average price is $127.65 and its 200 day moving average price is $121.39. The firm has a market cap of $23.65 billion, a price-to-earnings ratio of 33.38 and a beta of 1.20.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. The business had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The company’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.02 EPS. Equities research analysts predict that Zimmer Biomet Holdings will post $8.24 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.82%. Zimmer Biomet Holdings’s payout ratio is 27.59%.

In other news, VP Tony W. Collins sold 16,986 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Sang Yi sold 17,731 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. Parkside Financial Bank & Trust boosted its stake in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares in the last quarter. Parallel Advisors LLC boosted its stake in Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares in the last quarter. IHT Wealth Management LLC boosted its stake in Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares in the last quarter. Sandy Spring Bank boosted its stake in Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 20 shares in the last quarter. Finally, Penserra Capital Management LLC boosted its stake in Zimmer Biomet Holdings by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,288 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 112 shares in the last quarter. Institutional investors and hedge funds own 83.62% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/08/zimmer-biomet-holdings-inc-nysezbh-given-average-recommendation-of-hold-by-brokerages.html.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.